Brazil suspends Bharat Biotech's Covaxin clinical trials

| | Hyderabad
  • 0

Brazil suspends Bharat Biotech's Covaxin clinical trials

Saturday, 24 July 2021 | PTI | Hyderabad

Brazil suspends Bharat Biotech's Covaxin clinical trials

Brazil has suspended the Clinical studies of Bharat Biotech's COVID-19 vaccine, Covaxin following termination of the company's agreement with its partner there, the South American Country's health regulator said.

Bharat Biotech on Friday announced cancellation of the MoU it signed with Precisa Medicamentos and Envixia Pharmaceuticals LL.C for its COVID-19 vaccine Covaxin for the Brazilian market.

The termination of the pact comes after the deal with the Brazilian government for supply of 20 million doses of the vaccine landed in controversy and attracted investigation by authorities in that country.

"In the Coordination of Clinical Research at Anvisa (Copec/GGMED) determined this Friday (23/7) the precautionary suspension of clinical studies of the Covaxin vaccine in Brazil

The suspension was carried out as a result of a statement from the Indian company Bharat Biotech Limited International, sent to Anvisa on Friday (23/7), Anvisa, the Brazilian health regulator, said on Friday.

Precisa Medicamentos was Bharat Biotechs partner in Brazil, providing assistance, guidance and support with regulatory submissions, licensure, distribution, insurance and conduct of phase III clinical trials, among others.

Following the graft allegations, the Brazilian government has suspended Covaxin's order temporarily.

 

Sunday Edition

Pandemic: A Triple-Whammy for Parents

26 September 2021 | RamG Vallath | Agenda

Attached to none

26 September 2021 | Hingori | Agenda

Turn to art for progress

26 September 2021 | Aarrti Zaveri | Agenda

God is easily pleased

26 September 2021 | Ajit Kumar Bishnoi | Agenda

Astroturf : Living in demanding mode

26 September 2021 | Bharat Bhushan Padmadeo | Agenda

Meet India’s young writers

26 September 2021 | Shalini Saksena | Sunday Pioneer